Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Cash from Operations (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Cash from Operations for 13 consecutive years, with 4331000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 202.23% to 4331000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 11801000.0, a 19.86% decrease, with the full-year FY2025 number at 11801000.0, down 19.86% from a year prior.
  • Cash from Operations was 4331000.0 for Q4 2025 at Ekso Bionics Holdings, down from 2061000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1433000.0 in Q4 2024 to a low of 4331000.0 in Q4 2025.
  • A 5-year average of 2977250.0 and a median of 2989000.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: surged 56.53% in 2023, then plummeted 202.23% in 2025.
  • Ekso Bionics Holdings' Cash from Operations stood at 3075000.0 in 2021, then fell by 18.5% to 3644000.0 in 2022, then surged by 56.53% to 1584000.0 in 2023, then grew by 9.53% to 1433000.0 in 2024, then tumbled by 202.23% to 4331000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Cash from Operations are 4331000.0 (Q4 2025), 2061000.0 (Q3 2025), and 3444000.0 (Q2 2025).